Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (660)	3/15/2002 3:35:50 PM
From: Biomaven	Respond to of 1005

tuck, The PTIE release sounds too good to be true. <g> Of course it's only mice at this stage, but given there are unlikely to be tox issues in humans, reproducing the efficacy and side-effect profile in humans is going to be the key. I couldn't find the posters they mentioned on their website. Be nice if you could get Biotech Jim to comment here... Peter

To: tuck who wrote (660)	3/27/2002 10:16:13 AM
From: Biomaven	Read Replies (1) \| Respond to of 1005

tuck, The PTIE posters are now available on their web site: paintrials.com Looks pretty impressive to me. The dose of NTX they use seems to jump around - from as low as 1 picog/kg (!) in the oxycodone combo (shades of that flaky homeopathic dilution experiment) up to a few microg/kg. (on one slide only). Mostly the dose shown is 1 ng/kg. I'm back in the stock by the way, despite the skepticism about their work I hear from some (but not all) sources. If they get anything like this result in humans it will be a blockbuster. Safety should not be an issue, so mostly they have to show efficacy and overcome an FDA skeptical of combination drugs. They are probably also going to need some fairly big trials to iron out the dosage issues and see if there is in fact a male/female difference in humans. Peter